Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors, which are another class of oral glucose-lowering agents that prevent the reabsorption of glucose, can significantly affect cardiac function in models of DCM, providing a new and promising therapeutic option for DCM [84–86]. The gene discussed is SLC5A2; the disease is familial dilated cardiomyopathy.